• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巴林乳腺癌患者激素受体状态与年龄的相关性及其预后意义。

Correlation between hormone receptor status and age, and its prognostic implications in breast cancer patients in Bahrain.

作者信息

AlZaman Aysha S, Mughal Saad A, AlZaman Yahya S, AlZaman Entisar S

机构信息

Department of Oncology & Hematology, Salmaniya Medical Complex, Manama, Bahrain. E-mail.

出版信息

Saudi Med J. 2016 Jan;37(1):37-42. doi: 10.15537/smj.2016.1.13016.

DOI:10.15537/smj.2016.1.13016
PMID:26739972
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4724677/
Abstract

OBJECTIVES

To assess the correlation between hormone receptor status (HRS) and age, and its significance as a predictor of outcome in patients with breast cancer (BC).

METHODS

This retrospective review was conducted on 109 patients diagnosed with BC at Salmaniya Medical Complex, Manama, Bahrain from 2010-2013. Patients were divided into 2 age groups; under and over 40 years, and were analyzed for tumor histology, lymph node status, stage, and HRS.

RESULTS

Younger patients with BC were more likely to be of higher stage, grade, and of larger size. Older women were more likely to be estrogen receptor (ER) positive (72.6% versus 55.3%), and progesterone receptor (PR) positive (71% versus 53.2%) (p=0.03). The human epidermal growth factor receptor (HER)-2 over-expression was seen more in younger women (51% versus 40%) (p=0.2). Younger patients had higher lymph node metastases (88.6% versus 56.1%) (p=0.0004), and higher distant metastases (26.7% versus 6.8%) (p=0.005). The HER-2 over-expression strongly correlated with lymph node status. A total of 63.4% of lymph node positive patients had HER-2 over-expression compared with only 13.3% of lymph node negative patients (p less than 0.00001).

CONCLUSION

Breast cancer is more aggressive and advanced in younger women, a fact that can be significantly attributed to under expression of ER and PR, and over expression of HER-2, which also correlates well with lymph node status, as a measure of aggressiveness. Further studies should evaluate the genetic profile of BC in such population to improve their outcomes.

摘要

目的

评估激素受体状态(HRS)与年龄之间的相关性,及其作为乳腺癌(BC)患者预后预测指标的意义。

方法

对2010年至2013年在巴林麦纳麦萨勒曼尼亚医疗中心诊断为BC的109例患者进行回顾性研究。患者分为两个年龄组:40岁及以下和40岁以上,并对肿瘤组织学、淋巴结状态、分期和HRS进行分析。

结果

年轻的BC患者更有可能处于更高的分期、分级,肿瘤体积更大。老年女性更有可能雌激素受体(ER)阳性(72.6%对55.3%),孕激素受体(PR)阳性(71%对53.2%)(p = 0.03)。人表皮生长因子受体(HER)-2过表达在年轻女性中更为常见(51%对40%)(p = 0.2)。年轻患者有更高的淋巴结转移率(88.6%对56.1%)(p = 0.0004),以及更高的远处转移率(26.7%对6.8%)(p = 0.005)。HER-2过表达与淋巴结状态密切相关。共有63.4%的淋巴结阳性患者有HER-2过表达,而淋巴结阴性患者仅为13.3%(p小于0.00001)。

结论

年轻女性的乳腺癌更具侵袭性且病情更严重,这一事实可显著归因于ER和PR的低表达以及HER-2的过表达,而HER-2的过表达也与作为侵袭性指标的淋巴结状态密切相关。进一步的研究应评估该人群中BC的基因特征以改善其预后。

相似文献

1
Correlation between hormone receptor status and age, and its prognostic implications in breast cancer patients in Bahrain.巴林乳腺癌患者激素受体状态与年龄的相关性及其预后意义。
Saudi Med J. 2016 Jan;37(1):37-42. doi: 10.15537/smj.2016.1.13016.
2
Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.乳腺癌中Ki67的表达。沙特患者中与预后标志物及临床病理参数的相关性
Saudi Med J. 2016 Feb;37(2):137-41. doi: 10.15537/smj.2016.2.12285.
3
Ki-67 is a prognostic marker for hormone receptor positive tumors.Ki-67是激素受体阳性肿瘤的一个预后标志物。
Clin Transl Oncol. 2016 Oct;18(10):996-1002. doi: 10.1007/s12094-015-1472-y. Epub 2016 Jan 7.
4
[Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].[雌激素受体、孕激素受体及人表皮生长因子受体-2在接受乳房切除术的淋巴结阳性乳腺癌患者中的预后价值]
Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):520-5.
5
Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement.乳腺癌中雌激素受体和孕激素受体状态与年龄、组织学分级、病变大小及淋巴结受累情况的关系。
Asian Pac J Cancer Prev. 2012;13(10):5047-52. doi: 10.7314/apjcp.2012.13.10.5047.
6
Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.撒哈拉以南非洲地区的乳腺癌真的受体缺乏吗?肯尼亚乳腺癌中雌激素受体/孕激素受体/人表皮生长因子受体2的患病率。
Breast. 2014 Oct;23(5):591-6. doi: 10.1016/j.breast.2014.06.006. Epub 2014 Jul 7.
7
Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.乳腺癌中雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER-2/neu,即C-erb B 2)反应模式与组织学分级、肿瘤大小及淋巴结状态的比较
Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):553-6.
8
HER-2 positivity and correlations with other histopathologic features in breast cancer patients--hospital based study.乳腺癌患者中HER-2阳性及其与其他组织病理学特征的相关性——基于医院的研究
J Pak Med Assoc. 2006 Feb;56(2):65-8.
9
Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.雄激素受体表达预示早期三阴性乳腺癌患者生存率降低。
Ann Surg Oncol. 2015 Jan;22(1):82-9. doi: 10.1245/s10434-014-3984-z. Epub 2014 Aug 22.
10
Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.在早期随访期间,组织学分级为II级且伴有雌激素受体/孕激素受体(ER/PR)表达的绝经后、淋巴结阴性乳腺癌患者中,尿激酶型纤溶酶原激活剂(uPA)和纤溶酶原激活剂抑制剂-1(PAI-1)水平的潜在临床相关性。
Tumour Biol. 2015 Sep;36(10):8193-200. doi: 10.1007/s13277-015-3573-1. Epub 2015 May 21.

引用本文的文献

1
The Spectrum of Genetic Mutations Among Patients with Hereditary Breast and Ovarian Cancer.遗传性乳腺癌和卵巢癌患者的基因突变谱
J Clin Med. 2025 Jun 26;14(13):4536. doi: 10.3390/jcm14134536.
2
Effect of young age (below 40 years) on oncologic outcomes in Lebanese patients with breast cancer: a matched cohort study.年轻(<40 岁)对黎巴嫩乳腺癌患者肿瘤学结局的影响:一项匹配队列研究。
BMC Cancer. 2024 May 4;24(1):560. doi: 10.1186/s12885-024-11910-w.
3
Breast Cancer in the Arabian Gulf Countries.阿拉伯海湾国家的乳腺癌

本文引用的文献

1
Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers.由雌激素受体/孕激素受体/人表皮生长因子受体2亚型定义的乳腺癌生存率以及根据肿瘤分级和免疫组化生物标志物的替代分类
J Cancer Epidemiol. 2014;2014:469251. doi: 10.1155/2014/469251. Epub 2014 May 26.
2
Epidemiology of Breast Cancer among Bahraini Women: Data from the Bahrain Cancer Registry.巴林女性乳腺癌的流行病学:来自巴林癌症登记处的数据。
Sultan Qaboos Univ Med J. 2014 May;14(2):e176-82. Epub 2014 Apr 7.
3
Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
Cancers (Basel). 2023 Nov 14;15(22):5398. doi: 10.3390/cancers15225398.
4
Correlation Between Age and Hormone Receptor Status in Women With Breast Cancer.乳腺癌女性年龄与激素受体状态之间的相关性
Cureus. 2022 Jan 26;14(1):e21652. doi: 10.7759/cureus.21652. eCollection 2022 Jan.
5
Prevalence of Molecular Subtypes of Breast Carcinoma and Its Comparison between Two Different Age Groups: A Retrospective Study from a Tertiary Care Center of Northeast India.乳腺癌分子亚型的患病率及其在两个不同年龄组之间的比较:一项来自印度东北部三级医疗中心的回顾性研究。
South Asian J Cancer. 2021 Dec 31;10(4):220-224. doi: 10.1055/s-0041-1731905. eCollection 2021 Dec.
6
Silver Nanoparticles Modulate the Epithelial-to-Mesenchymal Transition in Estrogen-Dependent Breast Cancer Cells In Vitro.银纳米粒子在体外调节雌激素依赖性乳腺癌细胞的上皮间质转化。
Int J Mol Sci. 2021 Aug 25;22(17):9203. doi: 10.3390/ijms22179203.
7
Epidemiology of women diagnosed with breast cancer in Jordan: A 5-year survival analysis and patients' characteristics from 2 public hospitals.约旦被诊断患有乳腺癌的女性的流行病学:来自 2 家公立医院的 5 年生存分析和患者特征。
Saudi Med J. 2021 Jul;42(7):776-783. doi: 10.15537/smj.2021.42.7.20210112.
8
Frequency and clinical characteristics of HER2 over-expressed breast cancer in Saudi Arabia: a retrospective study.沙特阿拉伯 HER2 过表达型乳腺癌的频率和临床特征:一项回顾性研究。
BMC Womens Health. 2021 Jan 6;21(1):10. doi: 10.1186/s12905-020-01159-3.
9
Assessment of breast cancer immunohistochemistry and tumor characteristics in Nigeria.尼日利亚乳腺癌免疫组化及肿瘤特征评估
World J Clin Oncol. 2020 Nov 24;11(11):935-944. doi: 10.5306/wjco.v11.i11.935.
10
Molecular subtyping of mammary Paget's disease using immunohistochemistry.利用免疫组织化学对乳腺佩吉特病进行分子亚型分类。
Saudi Med J. 2019 May;40(5):440-446. doi: 10.15537/smj.2019.5.23967.
转移性乳腺癌亚型的预后:激素受体/HER2 阳性亚型与最佳结局相关。
Breast Cancer Res Treat. 2013 Oct;141(3):507-14. doi: 10.1007/s10549-013-2711-y. Epub 2013 Oct 9.
4
Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades.乳腺癌亚型和治疗对生存的影响:跨越二十年的分析。
Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1848-55. doi: 10.1158/1055-9965.EPI-12-0474. Epub 2012 Sep 18.
5
Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.三阴性乳腺癌中 BRCA 突变的流行率。
Cancer. 2012 Jun 1;118(11):2787-95. doi: 10.1002/cncr.26576. Epub 2011 Oct 5.
6
Breast cancer in women under 40 years of age.40岁以下女性的乳腺癌
J BUON. 2011 Oct-Dec;16(4):635-9.
7
Breast cancer statistics, 2011.乳腺癌统计数据,2011 年。
CA Cancer J Clin. 2011 Nov-Dec;61(6):409-18. doi: 10.3322/caac.20134. Epub 2011 Oct 3.
8
Breast cancer in the young patient.年轻患者的乳腺癌。
Am Surg. 2010 Dec;76(12):1397-400.
9
Breast cancer in young women.年轻女性乳腺癌。
Breast Cancer Res. 2010;12(5):212. doi: 10.1186/bcr2647. Epub 2010 Oct 28.
10
Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report.年龄/种族差异与乳腺癌三阴性亚型的 HER2 检测和发病率:一项基于人群的研究及首次报告。
Cancer. 2010 Jun 1;116(11):2549-59. doi: 10.1002/cncr.25016.